Point Biopharma Global

POINT Biopharma Global, Inc. is a precision oncology company, which engages in the development and commercialization of radiopharmaceuticals for the treatment of cancer. It offers CanSEEK, a technology which aims to minimize radiopharmaceutical toxicity caused by off-target delivery by only activating a radiopharmaceuticals' targeting moiety. The company was founded by Joe McCann and Neil E. Fleshner on April 15, 2020 and is headquartered in Indianapolis, IN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), manufacturing technology and novel direct-to-patient targeting to revolutionize theragnostic drug development and radioligand commercialization.

Dosimetry data demonstrated PNT2002 has a ​ favorable and safe dosimetry profile in the patient population and dose regimen being studied

POINT Biopharma Announces Abstract Publication of Dosimetry Data Findings from the Lead-In Cohort of the SPLASH trial in mCRPC at the 2022 SNMMI Mid-Winter & ACNM Annual Meeting

INDIANAPOLIS, Feb. 17, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced that the Company's Chief Executive Officer, Dr. Joe McCann will participate in the following upcoming investor conferences.

POINT Biopharma to Participate in Upcoming Virtual Investor Conferences

Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) inhibitor program, planned for summer 2022

POINT Biopharma Provides Early-Stage Program Updates

Company's radiopharmaceutical manufacturing facility now operational, supplying doses for the Phase 3 SPLASH trial – view the facility at manufacturing.pointbiopharma.com

POINT Biopharma Provides Update on Manufacturing, Supply Chain and Late-Stage Programs

Dr. Vincent brings more than 25 years of pharma business development experience along with deep technical expertise including drug development relating to oncology/immuno-oncology, inflammatory, and autoimmune disease Dr. Vincent brings more than 25 years of pharma business development experience along with deep technical expertise including drug development relating to oncology/immuno-oncology, inflammatory, and autoimmune disease

POINT Biopharma Adds Senior BD Expertise with Appointment of Dr. Matthew Vincent as SVP, Business Development

Justyna Kelly promoted to COO, Dr. Robin Hallett promoted to VP, Discovery and Translational Sciences, Dr. Sherin Al-Safadi to join as VP Medical Affairs, and Michael Gottlieb (CCO) to depart the Company to pursue other opportunities

POINT Biopharma adds a COO, Further Strengthens Leadership Team, and Announces Additional Board and Leadership Changes

POINT adds key technology to accelerate in-house no-carrier-added Lu-177 production POINT adds key technology to accelerate in-house no-carrier-added Lu-177 production

POINT Biopharma Licenses Innovative Lu-177 Production Technology from SCK CEN (Belgian Nuclear Research Center)

POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations

POINT Biopharma to Host Virtual Education Event on December 6, 2021

Initiated randomization phase of Phase 3 SPLASH study of PNT2002 in patients with metastatic castration-resistant prostate cancer (mCRPC)

POINT Biopharma Reports Third Quarter 2021 Financial Results and Provides Business Update

Supply agreement enables development of POINT's next-generation Ac-225-based radioligand therapies. Supply agreement enables development of POINT's next-generation Ac-225-based radioligand therapies.

POINT Biopharma and IONETIX Announce Ac-225 Supply Agreement

POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations on Dec 6, 2021 – register online at https://hub.pointbiopharma.com/dec2021

POINT Biopharma and Kinectrics Announce Yb-176 Supply Agreement Enabling North American Production of n.c.a. Lu-177

BURNABY, British Columbia--(BUSINESS WIRE)--ARTMS Inc. (ARTMS), the global leader in developing and commercializing novel products enabling cyclotron production of the world's most needed medical radioisotopes, is pleased to announce the submission of a Type 1 Master File with the Health Products & Food Branch, Health Canada (HC) for the production of gallium-68 (Ga-68). Gallium-68 is a critical medical isotope of significant clinical importance in nuclear medicine diagnostic procedures uti

ARTMS Inc. Announces Health Canada Submission for Ga-68 Production and Tri-party Collaboration to Advance Ga-68 Imaging Products

Point Biopharma Global Inc (NASDAQ: PNT) has additional preclinical data from its fibroblast activation protein-alpha (FAP-alpha) inhibitor program, PNT2004.  The new data demonstrate rapid and persistent tumor targeting with very low retention in normal tissues.

POINT Biopharma Posts New Preclinical Data, Exercises Option For FAP Inhibitor

Unique FAP targeting warhead combined with Actinium-225 or Lutetium-177 demonstrated complete tumor regression and long-term survival in preclinical models

POINT Biopharma Releases New Data and Exercises Option for Best-in-Class FAP Inhibitor

Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV 01-α (Rosopatamab-225Ac) in combination with PNT2002 for Progressive Metastatic Castration-Resistant Prostate Cancer

BELOIT, Wis. & INDIANAPOLIS--(BUSINESS WIRE)--NorthStar Medical Radioisotopes and POINT Biopharma have signed a supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).

NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

INDIANAPOLIS, Sept. 07, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life changing radiopharmaceuticals, today announced that the Company's Chief Executive Officer, Dr. Joe McCann will present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held from September 13-15, 2021.

POINT Biopharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Strengthened the Company's balance sheet by completing the business combination with Therapeutics Acquisition Corp (“RACA”), with gross proceeds from the transaction totaling approximately $286.7 million

POINT Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Update

News for Point Biopharma Global Stock (PNT)